Elsbernd Brian sold (to issuer) $7.6M of CPRX
Elsbernd Brian (Chief Legal Officer) sold (to issuer) 242,501 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($7.64M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The newest fact is the specific insider sale size, price, and post-transaction holdings (0 shares). This can influence sentiment but does not introduce new company fundamentals.
Market read
Primarily a sentiment/positioning datapoint for CPRX, with limited expected impact on valuation absent other catalysts.
What to watch
The code D indicates sale to the issuer, which often aligns with structured buyback or similar programs and may not reflect a bearish view on prospects.
Background
The article is an SEC Form 4 insider transaction disclosure for Catalyst Pharmaceuticals (CPRX).
Ticker impact
Catalyst Pharmaceuticals insider Form 4 shows Chief Legal Officer Elsbernd Brian sold 242,501 shares at $31.50 on 2026-07-15.
Likely minimal near-term impact; any effect is more signaling than fundamental.
The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying company news, guidance, or event beyond the sale mechanics.
Market effects
No clear sector read-through from a single insider sale without additional company-specific developments.
None.
None.
Counterpoint
The absence of a 10b5-1 plan could be interpreted by some traders as less routine, potentially increasing short-term skepticism.
Key entities
- issuerCATALYST PHARMACEUTICALS, INC.
CPRX, the company that received the insider sale to the issuer (Form 4 code D).
- insiderElsbernd Brian
Chief Legal Officer who sold 242,501 shares at $31.50 on 2026-07-15.